Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01631877
Other study ID # ILBS- PVT-01
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date June 2012
Est. completion date June 1, 2017

Study information

Verified date December 2016
Source Institute of Liver and Biliary Sciences, India
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

After successful screening the cases of cirrhosis of liver irrespective of the etiology who have non tumor portal vein thrombosis will be enrolled. The baseline Doppler parameter will be recorded and the patient will be randomized into either interventional (acenocoumarol) or placebo group along with first five days of subcutaneous Low Molecular Weight Heparin inj. Enoxaparin in the interventional arm and placebo injection in the control arm. Every 3 monthly the Doppler screening for recanalization of portal vein thrombus will be done with monitoring of International Normalized Ratio (INR)with target INR 2-3. Both the groups will receive the therapy for one year irrespective of the Doppler findings in relation to portal vein thrombus re-canalization.Then one year drug free monitoring will be done in both the groups as per the primary or secondary outcome. .


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 1, 2017
Est. primary completion date June 1, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- A clinical, radiological or histologic diagnosis of cirrhosis

- Partial or total Portal vein thrombus (evidence of chronic thrombus)

- Informed consent to participate in the study

Exclusion Criteria:

- Acute thrombus in Portal vein

- Hepatocellular carcinoma or any other malignancy,

- Hypercoagulable state other than the liver disease related

- DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.

- Base line INR >2

- Child Turcott Pugh score>11

- Recent peptic ulcer disease

- History of Hemorrhagic stroke

- Pregnancy.

- Uncontrolled Hypertension

- Age>70 yrs

- Non responders to beta-blocker requiring Endoscopic Variceal Ligation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Enoxaparin with acenocoumarol
enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR
Other:
placebo
injection placebo will be given for 5 days along with placebo tablets

Locations

Country Name City State
India Institute of Liver and Biliary Sciences. New Delhi Delhi

Sponsors (1)

Lead Sponsor Collaborator
Institute of Liver and Biliary Sciences, India

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportions of patients who will achieve Recanalization of thrombus (complete i.e No thrombus is seen or partial i.e up to 50% of the lumen become patent.)on oral anticoagulant acenocoumarol during the study period of 2 year from randomization. 2 years
Secondary Proportions of patients who will show improvement in Child Turcott Pugh (CTP) (>2 points)in both groups 2 years
Secondary Proportions of patients who will show improvement in Model for End Stage Liver Disease (MELD)(>4 points)in both groups 2 years
Secondary Proportions of patients who will achieve reduction in liver stiffness > 5 Kpa by transient elastography in both groups 2 years
Secondary Proportions of patients will show decrease in hepatic decompensation i.e hepatic encephalopathy,ascites,hepato renal syndrome,variceal bleed,jaundice and coagulopathy in both groups. 2 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03631147 - The Effect of Rifaximin on Portal Vein Thrombosis N/A
Completed NCT02250391 - Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis Phase 3
Recruiting NCT05625893 - Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion Phase 2
Completed NCT05012501 - Analysis of Neutrophil Extracellular Traps in Hypercoagulability and Portal Vein Thrombosis in Liver Cirrhosis Patients
Terminated NCT00769873 - Anticoagulation Post Laparoscopic Splenectomy Phase 2
Recruiting NCT05123326 - Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome
Completed NCT01095185 - Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding Phase 3
Completed NCT02585713 - Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism Phase 3
Not yet recruiting NCT06117488 - Risk Factors and Management Outcome of Chronic Portal Vein Thrombosis in Children
Completed NCT01326949 - Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis N/A
Not yet recruiting NCT05339581 - IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation N/A
Recruiting NCT03902678 - Role of EUS Guided FNA of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma N/A
Not yet recruiting NCT06319131 - Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT N/A
Recruiting NCT03193502 - Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis Phase 3
Completed NCT03201367 - Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV N/A
Completed NCT03477149 - EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications N/A
Recruiting NCT02398357 - The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Phase 4
Completed NCT01556282 - TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis N/A
Recruiting NCT04433481 - Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis N/A
Not yet recruiting NCT05872841 - H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis Phase 2